104 related articles for article (PubMed ID: 3366218)
1. Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas.
Martinsson U; Glimelius B; Hagberg H; Sundström C
Eur J Haematol; 1988 Apr; 40(4):289-98. PubMed ID: 3366218
[TBL] [Abstract][Full Text] [Related]
2. Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival.
Martinsson U; Glimelius B; Hagberg H; Sundström C
Eur J Haematol; 1989 Oct; 43(4):332-8. PubMed ID: 2583259
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
Hagberg H; Glimelius B; Gronowitz S; Killander A; Källander C; Schröder T
Scand J Haematol; 1984 Jul; 33(1):59-67. PubMed ID: 6379852
[TBL] [Abstract][Full Text] [Related]
4. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
[TBL] [Abstract][Full Text] [Related]
5. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum lactic dehydrogenase levels and fraction of S-phase cells in non-Hodgkin lymphomas.
Lindh J; Lenner P; Osterman B; Roos G
Eur J Haematol; 1993 May; 50(5):258-63. PubMed ID: 8319787
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers.
Christiansen I; Gidlof C; Kälkner K M; Hagberg H; Bennmarker H; Tötterman T
Br J Haematol; 1996 Mar; 92(3):639-46. PubMed ID: 8616029
[TBL] [Abstract][Full Text] [Related]
9. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
Rehn S; Gronowitz JS; Källander C; Sundström C; Glimelius B
Br J Cancer; 1995 May; 71(5):1099-105. PubMed ID: 7734308
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic significance of the histological classification and staging for patients with a malignant non-Hodgkin lymphoma].
Raemaekers JM; Snoeijen JJ; Bogman MJ; Rutten E; Strijk SP; Manni JJ
Ned Tijdschr Geneeskd; 1993 Apr; 137(16):815-20. PubMed ID: 8487885
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma.
Rehn S; Glimelius B; Strang P; Sundström C; Tribukait B
Hematol Oncol; 1990; 8(1):1-12. PubMed ID: 2298418
[TBL] [Abstract][Full Text] [Related]
12. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers.
Gronowitz JS; Steinholtz L; Källander CF; Hagberg H; Bergh J
Cancer; 1986 Jul; 58(1):111-8. PubMed ID: 3011236
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma.
Rehn S; Glimelius B; Sundström C
Hematol Oncol; 1991; 9(6):287-98. PubMed ID: 1748395
[TBL] [Abstract][Full Text] [Related]
14. [Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients].
García Zueco JC; Delgado MP; Giraldo MP; Perella M; Rubio-Félix D; Giralt M
Sangre (Barc); 1992 Oct; 37(5):337-44. PubMed ID: 1293772
[TBL] [Abstract][Full Text] [Related]
15. Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Heinz R; Hanak H; Stacher A
Klin Wochenschr; 1985 Jul; 63(14):619-26. PubMed ID: 3839867
[TBL] [Abstract][Full Text] [Related]
16. Prognostic parameters in low-grade non-Hodgkin's lymphomas.
Zemunik T; Vucković J; Forenpoher G; Knezević N; Stula N; Dubravcić M; Ribicić I; Rozga A
Neoplasma; 1997; 44(1):13-7. PubMed ID: 9201275
[TBL] [Abstract][Full Text] [Related]
17. Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas.
Iaffaioli RV; Frasci G; Palmieri G; Tagliaferri P; Montesarchio V; Pagliarulo C; Tortoriello A; Facchini G; Matano E; Lauria R
Leuk Lymphoma; 1995 Mar; 17(1-2):147-53. PubMed ID: 7773152
[TBL] [Abstract][Full Text] [Related]
18. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis.
Akerman M; Brandt L; Johnson A; Olsson H
Br J Cancer; 1987 Feb; 55(2):219-23. PubMed ID: 3814492
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
[TBL] [Abstract][Full Text] [Related]
20. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
